CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments

CureVac has revealed its financial results for Q2 and the first half of 2025. The company entered into a definitive Purchase Agreement with BioNTech, aiming to unite these German firms to enhance mRNA-based treatments globally. A significant step was resolving patent litigation with Pfizer/BioNTech over mRNA COVID-19 vaccines, establishing groundwork for global patent dispute resolution following BioNTech's acquisition of CureVac.

The company reported strong cash reserves of €392.7 million, projecting a financial runway into 2028. Revenues saw a dramatic 91% drop compared to last year, with Q2 revenues at €1.2 million. The decline was attributable to the restructuring of the GSK partnership and reduced sales to CRISPR Therapeutics.

Notably, CureVac secured CTA clearance from the EMA for its sqNSCLC cancer immunotherapy candidate. The glioblastoma study remains on track for data release in H2 2025. Overall, CureVac anticipates ongoing developments in oncology and infectious diseases research, marking a pivotal year despite financial challenges.